| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 8 | +87.50% | -11.40% | +2.30% | -13.70% | -16.50% | — |
| 14d | 8 | +87.50% | -7.61% | +1.64% | -9.25% | -7.77% | — |
| 30d | 8 | +87.50% | -11.74% | +2.31% | -14.05% | -12.31% | — |
| 60d | 8 | +75.00% | -5.02% | +5.79% | -10.82% | -20.70% | — |
| 90d | 8 | +75.00% | -6.38% | +6.77% | -13.15% | -22.41% | — |
| 180d | 8(1 pending) | +85.71% | -10.35% | +9.89% | -20.24% | -30.29% | — |
| 1y | 8(1 pending) | +42.86% | +7.48% | +27.39% | -19.91% | -15.08% | — |
| 2y | 8(1 pending) | +100.00% | -65.24% | +46.53% | -111.77% | -111.21% | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 60,000 | — | — | 60,000 | Feb 24, 2026 | Feb 26, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE CHIEF FINANCIAL OFFICER | 4,739 | $16.35 | $77.5K | 39,261 | Feb 18, 2026 | Feb 20, 2026 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 44,000 | — | — | 44,000 | Feb 18, 2025 | Feb 19, 2025 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 40,000 | — | — | 40,000 | Feb 13, 2024 | Feb 15, 2024 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE CHIEF FINANCIAL OFFICER | 40,000 | $16.00 | $640.0K | 40,000 | Jan 4, 2024 | Jan 24, 2025 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE CHIEF FINANCIAL OFFICER | 40,000 | $45.29 | $1.81M | 0 | Jan 4, 2024 | Jan 24, 2025 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Financial Officer | 40,000 | — | — | 53,622 | Jan 4, 2024 | Jan 8, 2024 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 40,000 | $16.00 | $640.0K | 40,000 | Nov 4, 2023 | Jan 8, 2024 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Financial Officer | 40,000 | $45.29 | $1.81M | 0 | Nov 4, 2023 | Jan 8, 2024 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 1,428 | $46.46 | $66.3K | 2,579 | Jun 9, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 15,993 | $45.03 | $720.2K | 4,007 | Jun 9, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,579 | $47.25 | $121.9K | 0 | Jun 9, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 20,000 | $16.00 | $320.0K | 20,000 | Jun 9, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Financial Officer | 20,000 | — | — | 93,622 | Jun 9, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 17,301 | $47.66 | $824.6K | 2,699 | Jun 8, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE Chief Financial Officer | 20,000 | — | — | 113,622 | Jun 8, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,699 | $48.65 | $131.3K | 0 | Jun 8, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 20,000 | $16.00 | $320.0K | 20,000 | Jun 8, 2023 | Jun 12, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 40,000 | — | — | 40,000 | Feb 16, 2023 | Feb 17, 2023 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 50,000 | — | — | 50,000 | Jan 21, 2022 | Jan 25, 2022 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 49,150 | — | — | 49,150 | Jan 10, 2021 | Jan 12, 2021 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 133,622 | — | — | 133,622 | Apr 7, 2020 | Apr 8, 2020 ↗ | View → |
| KROS KEROS THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 18,430 | — | — | 18,430 | Apr 7, 2020 | Apr 8, 2020 ↗ | View → |